ResearcherVA Nebraska Western Iowa Health Care SystemActive in the last 2 years
Apar Kishor Ganti
Matched on ORCID iD 0000-0003-3724-2671; OpenAlex author ID A5024497224. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 47
2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 11
- NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis. Last author DOI 10.1016/j.canlet.2026.218269↗
- Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.drup.2024.101146↗
- Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
- Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Co-author DOI 10.18632/oncotarget.25036↗
- Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data. Co-author DOI 10.1002/jso.24472↗
- Mortality following pancreatectomy for elderly rural veterans with pancreatic cancer. Last author DOI 10.1016/j.jgo.2017.05.001↗
- Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.3286↗
- Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3912↗
- Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells. Co-author DOI 10.1038/bjc.2014.152↗
- Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy. Co-author DOI 10.1016/j.canlet.2013.03.017↗
- Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering c… Co-author DOI 10.1016/j.canlet.2012.03.031↗
Closest collaborators
The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Surinder K. Batra · 9 shared papers, 2012–2026 · strength 0.88
- Paper NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXC… DOI 10.1016/j.canlet.2026.218269↗
- Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Imayavaramban Lakshmanan · 4 shared papers, 2015–2026 · strength 0.48
- Paper NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXC… DOI 10.1016/j.canlet.2026.218269↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in h… DOI 10.18632/oncotarget.3286↗
- Koelina Ganguly · 2 shared papers, 2024–2026 · strength 0.48
- Moorthy Palanimuthu Ponnusamy · 5 shared papers, 2014–2024 · strength 0.47
- Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in h… DOI 10.18632/oncotarget.3286↗
- Sanjib Chaudhary · 2 shared papers, 2022–2026 · strength 0.38
- Paper NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXC… DOI 10.1016/j.canlet.2026.218269↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Maneesh Jain · 3 shared papers, 2015–2024 · strength 0.37
- Paper Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma. DOI 10.1016/j.drup.2024.101146↗
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. DOI 10.18632/oncotarget.3912↗
- Satyanarayana Rachagani · 6 shared papers, 2012–2022 · strength 0.32
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in h… DOI 10.18632/oncotarget.3286↗
- Paper Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem c… DOI 10.1038/bjc.2014.152↗
- Sanchita Rauth · 2 shared papers, 2022–2024 · strength 0.32
- Ashu Shah · 2 shared papers, 2022–2024 · strength 0.32
- Muzafar Ahmad Macha · 2 shared papers, 2013–2026 · strength 0.31
- Paper NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXC… DOI 10.1016/j.canlet.2026.218269↗
- Paper Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro an… DOI 10.1016/j.canlet.2013.03.017↗
- Ramesh Pothuraju · 1 shared paper, 2026 · strength 0.27
- Jesse L. Cox · 1 shared paper, 2026 · strength 0.27
- Subodh M. Lele · 1 shared paper, 2026 · strength 0.27
- Parthasarathy Seshacharyulu · 3 shared papers, 2015–2022 · strength 0.21
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in h… DOI 10.18632/oncotarget.3286↗
- Paper Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. DOI 10.18632/oncotarget.3912↗
- Dhanya Haridas · 3 shared papers, 2015–2022 · strength 0.21
- Paper Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in panc… DOI 10.1038/s41388-022-02493-6↗
- Paper Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in h… DOI 10.18632/oncotarget.3286↗
- Paper Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. DOI 10.18632/oncotarget.3912↗
- Sushil Kumar · 1 shared paper, 2024 · strength 0.21
- Imran Khan · 1 shared paper, 2024 · strength 0.21
- Pranita Atri · 2 shared papers, 2018–2022 · strength 0.19
- Lynette M. Smith · 2 shared papers, 2018–2022 · strength 0.19
- Sushil Kumar K · 2 shared papers, 2018–2022 · strength 0.19
- Preethy Nayar · 2 shared papers, 2017 · strength 0.17
- Chandrakanth Are · 2 shared papers, 2017–2018 · strength 0.16
- Sakthivel Muniyan · 1 shared paper, 2022 · strength 0.11
- Seema C. Parte · 1 shared paper, 2022 · strength 0.11
- Geoffrey A. Talmon · 1 shared paper, 2022 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.